Repros Therapeutics Inc.
2408 Timberloch Place
Suite B-7
The Woodlands,
TX 77380
United States - Map
Phone: 281-719-3400
Fax: 281-719-3446
Web Site: http://www.reprosrx.com
| Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Its lead drug includes Proellex, a selective blocker of the progesterone receptor, which is in Phase III clinical trials for use as a pre-surgical treatment for women with anemia due to excessive menstrual bleeding associated with uterine fibroids, or anemia associated with uterine fibroids; in Phase III clinical trials for the chronic treatment of symptoms associated with uterine fibroids; and in Phase II clinical trials for the chronic treatment of symptoms associated with endometriosis. The companys product candidates also comprise Androxal, a single isomer of clomiphene citrate, which is in Phase IIb clinical trials for the treatment of low testosterone levels in men, who want to improve or maintain their fertility and/or sperm number and function. In addition, it holds a patent portfolio of phentolamine-based product candidates, including VASOMAX for the treatment of male erectile dysfunction under the Z-Max brand name. The company was formerly known as Zonagen, Inc. and changed its name to Repros Therapeutics Inc. in May 2006 to reflect companys focus on therapeutics for reproductive disorders. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Joseph S. Podolski , 62
Chief Exec. Officer |
N/A
| N/A | Dr. Jean L. Fourcroy M.D., Ph.D., MPH, 79
Chief Medical Officer, Director and Member of Nominating & Corp. Governance Committee |
$
20.00K | N/A | Dr. Ronald Wiehle Ph.D., 60
VP of R&D |
$
158.00K | N/A | Ms. Katherine Anderson , 51
Chief Accounting Officer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
0.01 (1.37%) 
Profile
